Alpha Tau Medical Earnings Call Transcripts
Fiscal Year 2026
-
Significant regulatory and clinical progress includes Japan's approval for head and neck cancer, near-completion of pivotal U.S. skin cancer trials, and promising pancreatic and GBM study updates. Strategic partnerships and a strong financial position support a transformative year ahead.
-
Alpha DaRT technology is advancing through pivotal clinical trials in skin, pancreatic, and brain cancers, with strong early data and a modular FDA submission strategy. Manufacturing scale-up is underway, and commercialization plans target direct U.S. sales and global partnerships.
-
A novel alpha particle-based cancer therapy is advancing through multiple pivotal and pilot trials, showing strong efficacy and safety across tumor types. Key regulatory milestones and manufacturing expansion are underway, with major data readouts and potential approvals expected in 2024.
Fiscal Year 2025
-
Recent milestones include first glioblastoma patient treated, strong interim pancreatic cancer data, and expanded U.S. trials. Regulatory progress and a robust cash position support plans for a major U.S. commercial launch by 2027, with broadening clinical applicability and growing investor interest.
-
A novel alpha radiation therapy platform is advancing through pivotal and pilot trials in skin, pancreatic, and brain cancers, showing high response rates and potential immune activation. Manufacturing expansion and a strong cash position support continued progress and regulatory submissions.
-
A novel alpha particle-based cancer therapy shows strong efficacy and safety across multiple tumor types, with pivotal trials underway in the US and promising results in metastatic and high unmet need cancers. Regulatory milestones and commercial launches are planned for the US, Japan, and beyond.
-
Alpha DaRT shows strong safety and efficacy across multiple tumor types, with promising results in pancreatic, liver, lung, and head and neck cancers. Regulatory progress and manufacturing scale-up support expansion, while combination with immunotherapy demonstrates enhanced responses.
-
A novel local alpha particle radiotherapy shows strong efficacy and safety across multiple tumor types, with regulatory progress in Israel, Japan, and the U.S. Ongoing trials target high unmet needs and metastatic disease, with key data readouts and financial stability supporting accelerated development.
Fiscal Year 2024
-
Alpha DaRT technology offers a novel, highly effective local treatment for solid tumors, showing 100% response in skin cancer trials and promising early results in pancreatic cancer. The therapy's safety, immune activation, and commercial potential are supported by ongoing pivotal studies and a strong financial position.